IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Ranbaxy Drops Out of Battle for Merck KGaA’s Generics Unit

1:43 PM MDT | March 28, 2007 | Deepti Ramesh

The largest pharma company in India, Ranbaxy Laboratories (Gurgaon) has dropped out of the second round of bidding for German pharma major, Merck KGaA’s generics business unit, according to a series of unconfirmed media reports at CW press time last week. The other companies believed to still be in the race for the generic unit are Teva Pharmaceuticals (Petach Tikva, Israel), Actavis (Reykjavik, Iceland), and Mylan Laboratories (Pittsburgh). The estimated worth of Merck’s generics business is around $6 billion, industry sources say. Ranbaxy declined...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa